Gyre Therapeutics (GYRE) AI Stock Analysis

• Market Cap: $636.78M
• Dividend Yield: N/A
• Average Volume (3M): 138.78K
• Price to Earnings (P/E): 147.2
• Beta (1Y): 1.16
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 579
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): 0.00
• Shares Outstanding: 90,323,265
• 10 Day Avg. Volume: 72,099
• 30 Day Avg. Volume: 138,785
• PEG Ratio: >-0.01
• Price to Book (P/B): 9.91
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -79.62
• Enterprise Value/Market Cap: 1.09
• Enterprise Value/Revenue: 176.79
• Enterprise Value/Gross Profit: -156.13
• Enterprise Value/Ebitda: -10.24
• 1Y Price Target: $24.25
• Price Target Upside: 233.56% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 53 Neutral
• Price Target: $8.00 ▲(10.04%Upside)

The overall score reflects a mixed financial performance with strong corporate event news. However, technical indicators and high valuation present challenges. The recent Phase 3 trial success is a positive catalyst, but financial and technical concerns limit the stock's attractiveness.

Gyre Therapeutics Business Overview & Revenue Model

Company Description

Gyre Therapeutics (GYRE) is a biotechnology company focused on developing innovative therapies for neurological disorders. Operating primarily in the pharmaceutical sector, Gyre specializes in the research and development of novel drug candidates aimed at treating a range of conditions including neurodegenerative diseases, psychiatric disorders, and pain management. The company leverages cutting-edge science and technology to create therapies that address unmet medical needs, positioning itself at the forefront of neurological treatment advancements.

How the Company Makes Money

Gyre Therapeutics generates revenue through several key streams. Primarily, the company monetizes its proprietary drug candidates by advancing them through clinical trials and subsequently licensing them to larger pharmaceutical companies for further development and commercialization. Additionally, Gyre may receive milestone payments based on the progress of these candidates during clinical phases and upon successful market entry. The company also explores partnerships with academic institutions and research organizations to collaborate on innovative research projects, which can provide funding and shared resources. Furthermore, Gyre may engage in grant applications and government funding opportunities to support its research initiatives, contributing to its overall revenue model.

Gyre Therapeutics Financial Statement Overview

Summary

Gyre Therapeutics shows mixed financial performance with improved profitability margins and return on equity in 2024. However, challenges remain in consistent revenue growth and cash flow generation, with a negative free cash flow trend raising sustainability concerns.

Income Statement

Gyre Therapeutics has shown significant volatility in its revenue and profitability metrics. The company experienced a substantial revenue drop from 2023 to 2024, followed by a recovery in gross profit margin to 96.3% in 2024. However, the net profit margin improved significantly to 11.4% in 2024 from a negative margin in 2023. Despite these improvements, the company has faced challenges with consistent revenue growth and profitability, as evidenced by the negative EBIT margin in prior years.

Balance Sheet

The balance sheet indicates a relatively stable financial position with a low debt-to-equity ratio of 0.03 in 2024, suggesting minimal leverage. The return on equity has improved to 19.1% in 2024, reflecting better profitability relative to equity. However, the equity ratio of 50.5% indicates moderate reliance on equity financing. The company's financial stability is supported by a positive stockholders' equity, but historical fluctuations in equity levels pose potential risks.

Cash Flow

Cash flow analysis reveals challenges in generating positive free cash flow, with a negative free cash flow of -$5.96 million in 2024. The operating cash flow to net income ratio is negative, indicating difficulties in converting income into cash flow. Despite these challenges, the company has managed to maintain some level of cash reserves, but the negative free cash flow trend raises concerns about sustainability.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	105.76M	113.45M	794.00K	7.34M	20.95M
Gross Profit	101.87M	108.81M	-4.00K	-42.00K	11.79M
EBITDA	17.82M	20.33M	10.33M	-87.60M	-57.37M
Net Income	12.09M	-92.93M	2.30M	-87.93M	-55.54M
Balance Sheet
Total Assets	125.41M	116.54M	28.44M	55.66M	94.85M
Cash, Cash Equivalents and Short-Term Investments	26.67M	33.51M	21.67M	46.85M	79.35M
Total Debt	1.60M	409.00K	38.00K	2.38M	1.64M
Total Liabilities	27.00M	38.06M	50.13M	14.57M	18.78M
Stockholders Equity	63.32M	-15.83M	-21.69M	41.09M	76.07M
Cash Flow
Free Cash Flow	-5.96M	17.31M	-38.09M	-84.59M	-55.31M
Operating Cash Flow	-3.64M	25.89M	-33.10M	-83.75M	-55.05M
Investing Cash Flow	-19.88M	-19.76M	55.43M	48.19M	9.66M
Financing Cash Flow	2.10M	2.50M	-45.01M	49.55M	60.38M

Gyre Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7.27
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GYRE, the sentiment is Negative. The current price of 7.27 is below the 20-day moving average (MA) of 7.44, below the 50-day MA of 8.02, and below the 200-day MA of 10.38, indicating a bearish trend. The MACD of -0.25 indicates Positive momentum. The RSI at 36.82 is Neutral, neither overbought nor oversold. The STOCH value of 13.69 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GYRE.

Gyre Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XERS	65 Neutral	$815.19M	―	222.83%	―	29.88%	35.11%
ABCL	59 Neutral	$1.33B	―	-15.59%	―	-35.41%	-12.26%
NTLA	56 Neutral	$1.21B	―	-57.92%	―	-13.37%	2.57%
GYRE	53 Neutral	$636.78M	147.18	11.62%	―	―	―
NRIX	52 Neutral	$844.00M	―	-50.67%	―	41.86%	10.48%
Sector *	51 Neutral	$7.30B	0.27	-62.71%	2.44%	15.02%	0.60%
PHVS	42 Neutral	$1.27B	―	-51.85%	―	―	0.71%

Gyre Therapeutics Corporate Events

Gyre Therapeutics Holds 2025 Annual Stockholders Meeting

On June 4, 2025, Gyre Therapeutics, Inc. conducted its 2025 Annual Meeting of Stockholders, where all director nominees were elected and other proposals were approved. The meeting included the election of Class I directors to serve until the 2028 Annual Meeting, approval of executive compensation on a non-binding basis, and ratification of Grant Thornton Zhitong Certified Public Accountants LLP as the independent auditor for 2025.

The most recent analyst rating on (GYRE) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Gyre Therapeutics stock, see the GYRE Stock Forecast page.

Gyre Therapeutics Announces Stock Offering Agreement

On May 22, 2025, Gyre Therapeutics, Inc. announced an underwriting agreement with Jefferies LLC to issue and sell 2,222,222 shares of common stock at $9.00 per share, with an option for underwriters to purchase an additional 333,333 shares. The company expects to raise approximately $18.5 million, which will be used to fund a Phase 2 clinical trial of F351 in the United States, as well as for research, development, and general corporate purposes. The offering is set to close on May 27, 2025, subject to customary conditions.

The most recent analyst rating on (GYRE) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Gyre Therapeutics stock, see the GYRE Stock Forecast page.

Gyre Therapeutics Achieves Key Milestone in Phase 3 Trial

On May 22, 2025, Gyre Therapeutics announced that its lead compound, Hydronidone, achieved the primary endpoint in a pivotal Phase 3 trial for treating liver fibrosis in patients with chronic hepatitis B in China. The 52-week trial demonstrated a statistically significant regression in liver fibrosis with Hydronidone compared to placebo, showing favorable safety and tolerability. This milestone positions Hydronidone as a potential first-in-class therapy for CHB-associated liver fibrosis, with plans for regulatory submission in China and further trials in the U.S.

The most recent analyst rating on (GYRE) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Gyre Therapeutics stock, see the GYRE Stock Forecast page.